UTHR - United Therapeutics Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
119.63
+1.09 (+0.92%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close118.54
Open119.05
Bid118.98 x 1200
Ask136.35 x 1100
Day's Range118.34 - 119.65
52 Week Range100.06 - 139.54
Volume227,148
Avg. Volume345,585
Market Cap5.214B
Beta (3Y Monthly)0.76
PE Ratio (TTM)9.69
EPS (TTM)12.34
Earnings DateFeb 19, 2019 - Feb 25, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est125.27
Trade prices are not sourced from all markets
  • Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
    Zacks3 days ago

    Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for

    United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Does United Therapeutics Corporation’s (NASDAQ:UTHR) CEO Salary Reflect Performance?
    Simply Wall St.3 days ago

    Does United Therapeutics Corporation’s (NASDAQ:UTHR) CEO Salary Reflect Performance?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Martine Rothblatt became the CEO of UnitedRead More...

  • Markit8 days ago

    See what the IHS Markit Score report has to say about United Therapeutics Corp.

    United Therapeutics Corp NASDAQ/NGS:UTHRView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for UTHR with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding UTHR totaled $1.24 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • PR Newswire16 days ago

    Survival Data From FREEDOM-EV Study of Orenitram Presented at the Pulmonary Vascular Research Institute Annual World Congress

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Jan. 31, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that key data from the FREEDOM-EV study of Orenitram® ...

  • GlobeNewswire19 days ago

    Report: Exploring Fundamental Drivers Behind Realty Income, United Therapeutics, NxStage Medical, PTC Therapeutics, AVEO Pharmaceuticals, and Owens & Minor — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Benzinga22 days ago

    The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stocks hit 52-week peaks Thursday. Down In The Dumps (Biotech stocks hitting 52-week lows on Jan. 24) Amneal ...

  • PR Newswire23 days ago

    United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag

    RESEARCH TRIANGLE PARK, N.C., Jan. 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) today announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (ARNA). Under the agreement, United Therapeutics acquired exclusive, worldwide rights to develop and manufacture the Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH).  Upon closing, United Therapeutics paid Arena $800 million. As previously announced, the closing of the transactions contemplated by the agreement was conditioned upon expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, among other conditions.

  • Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag
    PR Newswire23 days ago

    Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag

    SAN DIEGO, Jan. 24, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced the closing of the global license agreement with United Therapeutics Corporation (UTHR) for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension (PAH).  The global license agreement for ralinepag was announced on November 15, 2018. Ralinepag (APD811) is a next-generation, oral, selective potent, once-daily IP receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH).

  • MoCo economic development officials plan satellite office in Boston
    American City Business Journalslast month

    MoCo economic development officials plan satellite office in Boston

    Hey Boston, Montgomery County wants your biotech talent. In an unprecedented move, the Montgomery County Economic Development Corp. is in the early stages of planning an office in the Boston-Cambridge area to recruit companies from the region's rich biotech and life sciences industry. Bob Buchanan, a local developer who chairs the Montgomery County Economic Development Corp., told me Wednesday afternoon the corporation will hire real estate company JLL (NYSE: JLL) to conduct a life sciences market analysis, identify recruitment opportunities and propose potential locations for the office.

  • Did United Therapeutics Corporation (NASDAQ:UTHR) Insiders Sell Shares?
    Simply Wall St.last month

    Did United Therapeutics Corporation (NASDAQ:UTHR) Insiders Sell Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples Read More...

  • PR Newswire2 months ago

    United Therapeutics Corporation To Present At 37th Annual J.P. Morgan Healthcare Conference

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California. The presentation and the immediately following Q&A session will take place on Monday, January 7, 2019, at 2:30 PM Pacific Standard Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the "Investors" tab in the "Events and Presentations" section.

  • Stocks down in December for pharma firms in the Triangle
    American City Business Journals2 months ago

    Stocks down in December for pharma firms in the Triangle

    Pharmaceutical companies in the Triangle were far from exempt from a worldwide dive in stock prices, with some companies sliding more than 50 percent.

  • United Therapeutics Corporation (UTHR): Are Hedge Funds Right About This Stock?
    Insider Monkey2 months ago

    United Therapeutics Corporation (UTHR): Are Hedge Funds Right About This Stock?

    “Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back […]

  • Zacks Small Cap Research2 months ago

    MNKD: Zacks SCR Initiates Coverage of MannKind With $4.25/share Price Target

    Zacks SCR analysts Brian Marckx, CFA and Anita Dushyanth, PhD have initiated coverage of MannKind Corporation with a $4.25/share price target. MannKind Corporation (MNKD) was founded in the early 2000’s by the late Alfred Mann, a physicist by training, Mann was a pioneer in several fields including aerospace, electronics and medical devices. Among his successes prior to MannKind was development of the first rechargeable pacemaker and MiniMed, a revolutionary miniaturized insulin pump that was sold to Medtronic in 2001 for more than $3B.

  • Should You Be Excited About United Therapeutics Corporation’s (NASDAQ:UTHR) 20% Return On Equity?
    Simply Wall St.2 months ago

    Should You Be Excited About United Therapeutics Corporation’s (NASDAQ:UTHR) 20% Return On Equity?

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...

  • PR Newswire2 months ago

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of United Therapeutics Corporation - UTHR

    The investigation concerns whether United Therapeutics and certain of its officers and/or directors have breached fiduciary duties owed to the company and its investors. If you are a shareholder of United Therapeutics and are interested in obtaining additional information regarding this investigation,  you are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation.

  • United Therapeutics (UTHR) Up 2% Since Last Earnings Report: Can It Continue?
    Zacks3 months ago

    United Therapeutics (UTHR) Up 2% Since Last Earnings Report: Can It Continue?

    United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • PR Newswire3 months ago

    Health Canada Approves Unituxin® For The Treatment Of Pediatric High-Risk Neuroblastoma

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Nov. 29, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that Health Canada has approved Pr Unituxin (dinutuximab ...

  • Analysts: Why United Therapeutics has had a streak of licensing deals
    American City Business Journals3 months ago

    Analysts: Why United Therapeutics has had a streak of licensing deals

    United Therapeutics Corp. has been striking more licensing deals this year, a trend some analysts say illustrates the company’s strategy to staying ahead of generic competition. The Silver Spring drugmaker announced a global licensing agreement earlier this month with California company Arena Pharmaceuticals Inc. (NASDAQ: ARNA). United Therapeutics (NASDAQ: UTHR) will pay Arena $800 million upfront, plus up to $400 million in milestone payments, for exclusive rights to ralinepag, a phase 3 investigational drug candidate in development for pulmonary arterial hypertension.

  • United Therapeutics’ Product Portfolio in November
    Market Realist3 months ago

    United Therapeutics’ Product Portfolio in November

    United Therapeutics’ (UTHR) Remodulin generated revenues of $153.6 million in the third quarter, which reflected a decline of ~18% YoY (year-over-year).

  • United Therapeutics: A Financial Overview in November
    Market Realist3 months ago

    United Therapeutics: A Financial Overview in November

    United Therapeutics (UTHR) generated net revenues of $412.7 million in the third quarter—compared to $445.5 million during the third quarter of 2017, which reflected a decline of ~7% YoY (year-over-year). United Therapeutics’ net revenues during the first nine months of 2018 were $1.25 billion—compared to $1.26 billion during the same period in 2017, which reflected a decline of 1% YoY.

  • Zacks Small Cap Research3 months ago

    CORV: Topline Growth Accelerating

    Loss per share was ($0.20) as SG&A expenses grew reflecting an increase in the sales force. Newsflow during the third quarter continued to be very positive for Brinavess, and management has guided to a 2Q:19 resubmission to the FDA. Trevyent is now in the hands of United Therapeutics (UTHR) following their acquisition of SteadyMed.

  • United Therapeutics: Recent Developments and Analysts’ Ratings
    Market Realist3 months ago

    United Therapeutics: Recent Developments and Analysts’ Ratings

    On November 15, United Therapeutics (UTHR) entered into a global license agreement with Arena Pharmaceuticals (ARNA). According to the agreement, Arena Pharmaceuticals will provide United Therapeutics exclusive worldwide rights to develop, manufacture, and commercialize its investigational drug, ralinepag, to treat individuals with pulmonary arterial hypertension. Currently, ralinepag is in its Phase 3 clinical stage.